About Guanine nucleotide-binding protein G(z) subunit alpha
Guanine nucleotide-binding protein G(z) subunit alpha (GNAZ) is a protein
from Homo sapiens identified by UniProt accession
P19086, 355 residues long.
MolForge cross-references it against 0 known binders and
67 disease associations.
Target properties
| Protein name | Guanine nucleotide-binding protein G(z) subunit alpha |
|---|
| UniProt accession | P19086 |
|---|
| Gene | GNAZ |
|---|
| Organism | Homo sapiens |
|---|
| Length | 355 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (67)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.45
- vitamin D measurement · score 0.26
- lung adenocarcinoma · score 0.23
- head and neck squamous cell carcinoma · score 0.23
- esophageal cancer · score 0.23
- gastric adenocarcinoma · score 0.23
- urinary bladder cancer · score 0.20
- handedness · score 0.17
- nephrolithiasis · score 0.12
- urolithiasis · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P19086-F1 | alphafold | PREDICTED | 93.53 | — |
Amino-acid sequence (355 residues)
MGCRQSSEEK EAARRSRRID RHLRSESQRQ RREIKLLLLG TSNSGKSTIV KQMKIIHSGG FNLEACKEYK PLIIYNAIDS LTRIIRALAA LRIDFHNPDR AYDAVQLFAL TGPAESKGEI TPELLGVMRR LWADPGAQAC FSRSSEYHLE DNAAYYLNDL ERIAAADYIP TVEDILRSRD MTTGIVENKF TFKELTFKMV DVGGQRSERK KWIHCFEGVT AIIFCVELSG YDLKLYEDNQ TSRMAESLRL FDSICNNNWF INTSLILFLN KKDLLAEKIR RIPLTICFPE YKGQNTYEEA AVYIQRQFED LNRNKETKEI YSHFTCATDT SNIQFVFDAV TDVIIQNNLK YIGLC
Explore Guanine nucleotide-binding protein G(z) subunit alpha with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets